Benzodiazepine
Benzodiazepine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AE: Benzodiazepine derivative antiepileptics
— N05: Psycholeptics
— N05B: Anxiolytics
— N05BA: Benzodiazepine derivative anxiolytics
— N05C: Hypnotics and sedatives
— N05CD: Benzodiazepine derivative hypnotics and sedatives
— N05CF: Benzodiazepine related hypnotics and sedatives
HCPCS
Code | Description |
|---|---|
| G0033 | Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between january 1 of the year prior to the measurement period and the ipsd for benzodiazepines |
Clinical
Clinical Trials
327 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 3 | 1 | 2 | 18 | 23 |
| Depression | D003863 | — | F33.9 | — | 4 | 2 | 5 | 9 | 18 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | 2 | 7 | 8 | 18 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | — | 1 | 4 | 10 | 16 |
| Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | — | — | 5 | 9 | 14 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 1 | — | 4 | 9 | 14 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 4 | 2 | 4 | 6 | 14 |
| Delirium | D003693 | — | R41.0 | 2 | — | — | 3 | 8 | 13 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | 2 | 9 | 12 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | 5 | 5 | 11 |
Show 57 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 2 | 3 | — | 3 | 8 |
| Anesthesia | D000758 | — | — | 2 | — | 1 | — | 4 | 7 |
| Seizures | D012640 | HP_0002069 | G40.4 | — | 2 | 1 | — | 3 | 5 |
| Neonatal abstinence syndrome | D009357 | EFO_0005799 | P96.1 | 1 | 1 | 1 | — | 2 | 4 |
| Artificial respiration | D012121 | — | — | — | — | 1 | — | 2 | 3 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 2 | 1 | — | 1 | 3 |
| Drug resistant epilepsy | D000069279 | — | — | — | 1 | 1 | — | 1 | 2 |
| Critical illness | D016638 | — | — | — | — | 2 | — | — | 2 |
| Covid-19 | D000086382 | — | — | — | — | 1 | — | 1 | 2 |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | 1 | — | 1 | 2 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | 2 | — | — | 5 | 19 |
| Drug overdose | D062787 | — | — | — | 1 | — | — | 3 | 4 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | 2 | — | — | 2 | 4 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | 1 | 1 | — | — | 2 | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 2 | 3 |
| Acute pain | D059787 | — | R52 | — | 1 | — | — | 1 | 2 |
| Emergencies | D004630 | — | — | 1 | 1 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | 1 | 2 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Emergence delirium | D000071257 | — | — | 1 | — | — | — | 4 | 5 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | 1 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 2 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | — | 1 | 2 |
| Infarction | D007238 | EFO_0009463 | — | 1 | — | — | — | 1 | 2 |
| Sclerosis | D012598 | — | — | 2 | — | — | — | — | 2 |
| Neurocysticercosis | D020019 | — | — | 2 | — | — | — | — | 2 |
| Cysticercosis | D003551 | EFO_0007231 | B69 | 2 | — | — | — | — | 2 |
| Taeniasis | D013622 | EFO_1001433 | B68 | 2 | — | — | — | — | 2 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 6 | 6 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 5 | 5 |
| Deprescriptions | D000069340 | — | — | — | — | — | — | 4 | 4 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 3 | 3 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 3 | 3 |
| Narcotic-related disorders | D000079524 | — | — | — | — | — | — | 2 | 2 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | — | — | — | 2 | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 2 | 2 |
Show 124 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Benzodiazepine |
| INN | — |
| Description | Benzodiazepines (BZD, BDZ, BZs), colloquially called "benzos", are a class of depressant drugs whose core chemical structure is the fusion of a benzene ring and a diazepine ring. They are prescribed to treat conditions such as anxiety disorders, insomnia, and seizures. The first benzodiazepine, chlordiazepoxide (Librium), was discovered accidentally by Leo Sternbach in 1955 and was made available in 1960 by Hoffmann–La Roche, who soon followed with diazepam (Valium) in 1963. By 1977, benzodiazepines were the most prescribed medications globally; the introduction of selective serotonin reuptake inhibitors (SSRIs), among other factors, decreased rates of prescription, but they remain frequently used worldwide.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1=Cc2ccccc2NN=C1 |
Identifiers
| PDB | — |
| CAS-ID | 12794-10-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297264 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,043 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,521 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use